Optimal patient selection for trastuzumab treatment in HER2-Positive advanced gastric cancer

Clinical Cancer Research

Volumn 21, Issue 11, 2015, Pages 2520-2529

  Ock, Chan Young ^a   Lee, Keun Wook ^b   Kim, Jin Won ^b   Kim, Jin Soo ^c   Kim, Tae Yong ^a,d   Lee, Kyung Hun ^a,d   Han, Sae Won ^a,d   Im, Seock Ah ^a,d   Kim, Tae You ^a,d   Kim, Woo Ho ^a   Bang, Yung Jue ^a,d   Oh, Do Youn ^a,d  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ADVANCED CANCER; ADVANCED GASTRIC CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HER2 CEP17 RATIO; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; STOMACH CANCER; CANCER STAGING; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84941959187     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2659     Document Type: Article

References (26)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010:CD004064.
3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
4. FDA AU. Full prescribing information for trastuzumab. 2010. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/103792s5250lbl.pdf.
5. EMA AE. Summary of positive opinion for herceptin. 2009. Available from: www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion/human/000278/WC500059913.pdf.
6. Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, et al. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer 2014;110: 1163-8.
7. Gravalos C, Gomez-Martin C, Rivera F, Ales I, Queralt B, Marquez A, et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 2011;13:179-84.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
10. Guiu S, Gauthier M, Coudert B, Bonnetain F, Favier L, Ladoire S, et al. Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. Br J Cancer 2010;103:1335-42.
11. Gullo G, Bettio D, Torri V, Masci G, Salvini P, Santoro A. Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer. Invest New Drugs 2009;27:179-83.
12. Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol 2013;31:4445-52.
13. Im SA, Kim JW, Kim JS, Kim MA, Jordan B, PicklM, et al. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. Diagn Mol Pathol 2011;20:94-100.
14. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, SargentD, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
16. Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, et al. Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patientdata meta-Analysis. Eur J Cancer 2013;49:1565-77.
17. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988;44:837-45.
18. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006;15:65-71.
19. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004; 22:2395-403.
20. Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, et al. Longterm survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol 2004;34:654-9.
21. Koo DH, Ryoo BY, Kim HJ, Ryu MH, Lee SS, Moon JH, et al. A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. Cancer Chemother Pharmacol 2011;68:913-21.
22. Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ, et al. Prognostic significance of a systemic inflammatory response in patients receiving firstline palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer 2011;11:489.
23. Wolff AC, HammondME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
24. Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, et al. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 2013; 138:99-108.
25. Hecht JR, Bang YJ, Qin S, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC trial. J Clin Oncol 31, 2013 (suppl; abstr LBA4001).
26. Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-Amplified advanced gastric cancer in Asian populations: TyTAN-A randomized, phase III study. J Clin Oncol 2014;32:2039-49.